CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| E2100 | ECOG | A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| GOG-0250 | GOG | A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297 | Adult CIRB - Late Phase Emphasis | Completed |
| S2101 | SWOG | Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GI002 | NRG | A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| S0221 | SWOG | Phase III Trial of Continuous Schedule AC+G Vs. Q2 Week Schedule AC; Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA5181 | ECOG-ACRIN | Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GI007 | NRG | Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1934 | SWOG | NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| NCCTG-N06C6 | NCCTG | A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases | Adult CIRB - Late Phase Emphasis | Completed |
| A042001 | Alliance | A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-cell Acute Lymphoblastic Leukemia | Adult CIRB - Late Phase Emphasis | Available to Open |